AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

  • Views:

    Views Icon 1600

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

  • To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
  • Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
  • Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Watch now

Part 3

Expert Interviews

4 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Watch now

Part 4

Highlights

1 session
Coming Soon Watch now

About the episode

AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.

 

Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).

 

LIBerate-HeFH_OLE is an open-label extension study investigating the use of lerodalcibep alongside oral lipid-lowering therapy in patients with CVD including HoFH who have successfully completed one of the phase 3 base studies. 703 patients were enrolled in the study and were followed-up after 48 and 72 weeks. The primary outcome measure was the incidence of treatment-emergent adverse events.

 

Interview Questions:

1.     What was the reasoning and the design behind the study?
2.    What are the take-home messages for practice? 
3.    What further research is needed in this area?

 

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers:  Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Frederick Raal

Frederick Raal

Professor and Director of the Carbohydrate and Lipid Metabolism Research Unit

Professor Frederick Raal is a distinguished Professor and the Director of the Carbohydrate and Lipid Metabolism Research Unit at the University of the Witwatersrand in Johannesburg, South Africa. He also serves as the Head of the Division of Endocrinology and Metabolism at the same institution.

He graduated with an MBBCh degree in 1981, followed by a Master of Medicine in 1991, a PhD in 2000, and a Doctor of Science in 2022. Throughout his career, Professor Raal has earned several prestigious postgraduate awards, including the TH Bothwell Research Prize, the FJ Milne Award, and the Vice Chancellor’s Research Award from the University of the Witwatersrand.

He has authored hundreds of original articles and book chapters and served as a reviewer for several leading international journals, including the New England Journal of Medicine, The Lancet, Circulation, and Atherosclerosis. Additionally, he sits on the Editorial Board of Atherosclerosis, co-edits Current Opinion in…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.